Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation
- 4 March 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (8), 1123-1128
- https://doi.org/10.1161/01.cir.0000053559.46158.ad
Abstract
Background— Glycoprotein (GP) IIb/IIIa antagonists inhibit platelet aggregation, an activity attributed to the clinical benefits of these drugs in settings that involve acute coronary thrombosis. H...Keywords
This publication has 30 references indexed in Scilit:
- Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on plateletsHeart, 2001
- Inflammatory role of platelets in acute coronary syndromesHeart, 2001
- Differential Antiplatelet Effects of Various Glycoprotein IIb–IIIa AntagonistsThrombosis Research, 2001
- Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrelPlatelets, 2001
- Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive diseaseBlood Coagulation & Fibrinolysis, 2000
- T Lymphocytes Induce Endothelial Cell Matrix Metalloproteinase Expression by a CD40L-Dependent MechanismThe American Journal of Pathology, 1999
- Reduction of atherosclerosis in mice by inhibition of CD40 signallingNature, 1998
- A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cellsNature, 1997
- Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3Cell, 1996
- Expression of functional CD40 by vascular endothelial cells.The Journal of Experimental Medicine, 1995